• License provides Access to Genome Editing Platform
  • Eric Rhodes
  • Sunghwa Choe

News & Views

License provides Access to Genome Editing Platform

G+FLAS Life Sciences, has been granted a non-exclusive license agreement to access to ERS Genomics’ CRISPR/Cas9 patent portfolio. The Korean biotech (Seoul) produces research tools and reagents under ISO 13485 and ISO 9001 and is applying CRISPR PLUS technology to the development of drugs and production of CRISPR genome edited plants in a non-GMO way.

ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.

“G+FLAS is developing genome editing applications using CRISPR/Cas9 that will further expand the reach of this important gene editing tool,” said Eric Rhodes, CEO of ERS Genomics. “We are pleased to provide access to this Nobel Prize winning technology and look forward to seeing G+FLAS continue in its mission.”

“We are very excited to sign this licensing agreement with ERS Genomics, to build on the strength of our existing platform and drive our future growth,” said Sunghwa Choe, CEO of G+FLAS Life Sciences. “Based on our advanced CRISPR PLUS research technology and global-standard production process, we will continue to innovate to meet our clients’ needs, to make differences in their discovery processes.”

Financial details of the agreement were not disclosed.


Digital Edition

Lab Asia 31.6 Dec 2024

December 2024

Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...

View all digital editions

Events

Smart Factory Expo 2025

Jan 22 2025 Tokyo, Japan

Instrumentation Live

Jan 22 2025 Birmingham, UK

SLAS 2025

Jan 25 2025 San Diego, CA, USA

Arab Health

Jan 27 2025 Dubai, UAE

Nano Tech 2025

Jan 29 2025 Tokyo, Japan

View all events